REVIEW
SA JOURNAL OF DIABETES & VASCULAR DISEASE
18
VOLUME 8 NUMBER 1 • MARCH 2011
References
1.
Rohdenburg GL. Thyroid diabetes.
Endocrinology
1920;
4
: 63.
2.
Lenzen S, Bailey CJ. Thyroid hormones, gonadal and adrenocortical steroids and
the function of the islets of Langerhans.
Endocr Rev
1984;
5
: 411–34.
3.
Boelaert K, Franklyn JA. Thyroid hormone in health and disease.
J Endocrinol
2005;
187
: 1–15.
4.
Hollowell JG, Staehling NW, Flanders WD,
et al.
Serum TSH, T(4), and thyroid
antibodies in the United States population (1988 to 1994): National Health and
Nutrition Examination Survey (NHANES III).
J Clin Endocrinol Metab
2002;
87
:
489–99.
5.
Canaris GJ, Manowitz NR, Mayor G,
et al.
The Colorado thyroid disease
prevalence study.
Arch Intern Med
2000;
160
: 526–34.
6.
Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and
antithyroid antibodies in the US population: implications for the prevalence of
subclinical hypothyroidism.
J Clin Endocrinol Metab
2007;
92
: 4575–82.
7.
Wiersinga WM. Subclinical hypothyroidism and hyperthyroidism. I. Prevalence
and clinical relevance.
Neth J Med
1995;
46
: 197–204.
8.
Pearce SH, Merriman TR. Genetics of type 1 diabetes and autoimmune thyroid
disease.
Endocrinol Metab Clin N Am
2009;
38
: 289–301.
9.
Perros P, McCrimmon RJ, Shaw G,
et al.
Frequency of thyroid dysfunction in
diabetic patients: value of annual screening.
Diabet Med
1995;
12
: 622–7.
10. Kordonouri O, Maguire AM, Knip M,
et al.
Other complications and associated
conditions with diabetes in children and adolescents.
Pediatric Diabetes
2009;
10
: 204–10.
11. Abalovich M, Amino N, Barbour LA,
et al.
Management of thyroid dysfunction
during pregnancy and postpartum: An Endocrine Society clinical practice
guideline.
J Clin Endocrinol Metab
2007;
92
: S1–47.
12. Chubb SA, Davis WA, Inman Z. Prevalence and progression of subclinical
hypothyroidism in women with type 2 diabetes: the Fremantle Diabetes Study.
Clin Endocrinol (Oxf)
2005;
62
: 480–6.
13. Gambelunghe G, Forini F, Laureti S,
et al.
Increased risk for endocrine
autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies.
Clin
Endocrinol
2000;
52
: 565–73.
14. Libman IM, Sun K, Foley TP, Becker DJ. Thyroid autoimmunity in children with
features of both type 1 and type 2 diabetes.
Pediatr Diabetes
2008;
9
: 266–71.
15. Uzunlulu M, Yorulmaz E, Og˘uz A. Prevalance of subclinical hypothyroidism in
patients with metabolic syndrome.
Endocr J
2007;
54
: 71–6.
16. Standards of medical care in diabetes: 2008.
Diabetes Care
2008;
31
(suppl 1):
S12.
17. Kordonouri O, Maguire AM, Knip M,
et al.
International Society for Pediatric and
Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2006–2007.
Other complications and associated conditions.
Pediatr Diabetes
2007;
8
: 171–6.
18. Raboudi N, Arem R, Jones RH,
et al.
Fasting and postabsorptive hepatic glucose
and insulin metabolism in hyperthyroidism.
Am J Physiol
1989;
256
: E159–66.
19. Weinstein SP, O’Boyle E, Fisher M, Haber RS. Regulation of GLUT2 glucose
transporter expression in liver by thyroid hormone: evidence for hormonal
regulation of the hepatic glucose transport system.
Endocrinology
1994:
135
:
649–54.
20. Viguerie N, Millet L, Avizou S,
et al.
Regulation of human adipocyte gene
expression by thyroid hormone.
J Clin Endocrinol Metab
2002;
87
: 630–4.
21. Clément K, Viguerie N, Diehn M,
et al.
In vivo regulation of human skeletal
muscle gene expression by thyroid hormone.
Genome Res
2002;
12
: 281–91.
22. Moeller LC, Dumitrescu AM, Walker RL,
et al.
Thyroid hormone responsive genes
in cultured human fibroblasts.
J Clin Endocrinol Metab
2005;
90
: 936–43.
23. Potenza M, Via MA, Yanagisawa RT,
et al.
Excess thyroid hormone and
carbohydrate metabolism.
Endocr Pract
2009;
15
: 254–62.
24. Dimitriadis G, Baker B, Marsh H,
et al.
Effect of thyroid hormone excess on
action, secretion, and metabolism of insulin in humans.
Am J Physiol
1985;
248
:
E593–601.
25. Muller MJ, Acheson KJ, Jequier E, Burger AG. Effect of thyroid hormones on
oxidative and nonoxidative glucose metabolism in humans.
Am J Physiol
1988;
255
: E146–52.
26. Shen DC, Davidson MB, Kuo SW, Sheu WH. Peripheral and hepatic insulin
antagonism in hyperthyroidism.
J Clin Endocrinol Metab
1988;
66
: 565–9.
27. Dimitriadis G, Mitrou P, Lambadiari V,
et al.
Insulin-stimulated rates of glucose
uptake in muscle in hyperthyroidism: the importance of blood flow.
J Clin
Endocrinol Metab
2008;
93
: 2413–15.
28. Ortega E, Koska J, Pannacciulli N,
et al.
Free triiodothyronine plasma
concentrations are positively associated with insulin secretion in euthyroid
individuals.
Eur J Endocrinol
2008;
158
: 217–21.
29. Ximenes HM, Lortz S, Jörns A, Lenzen S. Triiodothyronine (T3)-mediated toxicity
and induction of apoptosis in insulin-producing INS-1 cells.
Life Sci
2007;
80
:
2045–50.
30. Rochon C, Tauveron I, Dejax C,
et al.
Response of glucose disposal to
hyperinsulinemia in human hypothyroidism and hyperthyroidism.
Clin Sci
2003;
104
: 7–15.
31. Handisurya A, Pacini G, Tura A,
et al.
Effects of thyroxine replacement therapy on
glucose metabolism in subjects with subclinical and overt hypothyroidism.
Clin
Endocrinol (Oxf)
2008;
69
: 963–9.
32. Dimitriadis G, Mitrou P, lambadiari V,
et al.
Insulin action in adipose tissue and
muscle in hypothyroidism. J
Clin Endocrinol Metab
2006;
91
: 4930–7.
33. Brenta G, Celi FS, Pisarev M,
et al.
Acute thyroid hormone withdrawal in athyreotic
patients results in a state of insulin resistance.
Thyroid
2009;
19
: 665–9.
34. Andreani D, Menzinger G, Fallucca F,
et al.
Insulin levels in thyrotoxicosis and
primary myxoedema: response tointravenous glucose and glucagon.
Diabetologia
1970;
6
: 1–7.
35. Maratou E, Hadjidakis DJ, Kollias A,
et al.
Studies of insulin resistance in patients
with clinical and subclinical hypothyroidism.
Eur J Endocrinol
2009;
160
: 785–90.
36. Müller MJ, Paschen U, Seitz HJ. Thyroid hormone regulation of glucose
homeostasis in the miniature pig.
Endocrinology
1983;
112
: 2025–31.
37. Okajima F, Ui M. Metabolism of glucose in hyper and hypothyroid rats
in vivo
.
Glucose turnover values and futile cycle activities obtained with
14
C and
3
H
labelled glucose.
Biochem J
1979;
182
: 565–75.
38. McCulloch AJ, Nosadini r, Pernet A,
et al.
Glucose turnover and indices of
recycling in thyrotoxicosis and primary thyroid failure.
Clin Sci
1983;
64
: 41–7.
39. Bakker SJ, ter Maaten JC, Popp-Snijders C. The relationship between thyrotropin
and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy
euthyroid subjects.
J Clin Endocrinol Metab
2001;
86
: 1206–11.
40. Chubb SA, Davis WA, Davis TM. Interactions among thyroid function, insulin
sensitivity, and serum lipid concentrations: The Fremantle Diabetes Study.
J Clin
Endocrinol Metab
2005;
90
: 5317–20.
41. Chidakel A, Mentuccia D, Celi FS. Peripheral metabolism of thyroid hormone and
glucose homeostasis.
Thyroid
2005;
15
: 899–903.
42. Surks MI, Ortiz E, Daniels GH,
et al.
Subclinical thyroid disease: scientific review
and guidelines for diagnosis and management.
J Am Med Assoc
2004;
291
:
228–238.
43. Brown J, Solomon DH. Mechanism of antithyroid effects of a sulfonylurea in the
rat.
Endocrinology
1958;
63
: 473.
44. Cappelli C, rotondi M, Pirola I,
et al.
TSH-lowering effect of metformin in type2
diabetic patients. Differences between euthyroid, untreated hypothyroid and
euthyroid on l-T4 therapy patients.
Diabetes Care
2009;
32
: 1589–90.
45. Starkey K, Heufelder A, Baker G,
et al.
Peroxisome proliferator-activated receptor-
gamma in thyroid eye disease: contraindication for thiazolidinedione use?
J Clin
Endocrinol Metab
2003;
88
: 55–9.
46. Venero CV, Thompson PD. Managing statin myopathy.
Endocrinol Metab Clin
North Am
2009;
38
: 121–36.
47. Brenta G, Danzi S, Klein I. Potential therapeutic applications of thyroid hormone
analogs.
Nat Clin Pract Endocrinol Metab
2007;
3
: 632–64.
48. Baxter J, Webb P. Thyroid hormone mimetics: potential applications in athero-
sclerosis, obesity and type 2 diabetes.
Nat Rev Drug Discov
2009;
8
: 308–20.
49. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction.
Endocr Rev
2008;
29
: 76–131.
50. Chen HS, Wu TE, Jap TS,
et al.
Subclinical hypothyroidism is a risk factor for
nephropathy and cardiovascular diseases in type 2 diabetic patients.
Diabet Med
2007;
24
: 1336–44.
51. Yang JK, liu W, Shi J, li YB. An association between subclinical hypothyroidism
and sight-threatening diabetic retinopathy in type 2 diabetic patients.
Diabetes
Care
2010;
33
: 1018–20.
52. Haentjens P, Van Meerhaeghe A, Poppe K,
et al.
Subclinical thyroid dysfunction
and mortality: an estimate of relative and absolute excess all-cause mortality
based on time-to-event data from cohort studies.
Eur J Endocrinol
2008;
159
:
329–41.
53. Sathyapalan T, Manuchehri AM, rigby AS, Atkin Sl. Subclinical hypothyroidism
is associated with reduced all-cause mortality in patients with type 2 diabetes.
Diabetes Care
2010;
33
: e37.
54. Ochs N, Auer r, Bauer DC,
et al.
Meta-analysis: subclinical thyroid dysfunction
and the risk for coronary heart disease and mortality.
Ann Intern Med
2008;
148
: 832–45.
55. Razvi S, Shakoor A, Vanderpump M,
et al.
The influence of age on the relationship
between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. J
Clin Endocrinol Metab
2008;
93
: 2998–3007.
